Prof. Heng Mei, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Prof. Jingjing Feng, The First Affiliated Hospital, Zhejiang University School of Medicine, China
Prof. Jean-Marie Michot, Gustave Roussy, France
Prof. Mei, Prof. Feng and Prof. Michot discussed the most significant advances in CAR-T therapy in 2025, including progress in novel targets, bispecific approaches, and safety optimization. They also explored how the treatment landscape is evolving through earlier-line use, expanded indications, and emerging combination strategies.